⌘K

Login Start Free

Home/Filings/4/0001714899-25-000149

4//SEC Filing

Watts Ryan J. 4

Accession 0001714899-25-000149

CIK 0001714899other

View on SEC.gov Company Profile

Filed

Jul 10, 8:00 PM ET

Accepted

Jul 11, 5:13 PM ET

Size

13.7 KB

Accession

0001714899-25-000149

Insider Transaction Report

Form 4

Period: 2025-07-09

Denali Therapeutics Inc.DNLI

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
2025-07-09$5.28/sh+40,000$211,200→ 748,353 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-09−40,000→ 20,369 total
Exercise: $5.28Exp: 2027-03-07→ Common Stock (40,000 underlying)
Exercise/Conversion
Common Stock
2025-07-09$0.68/sh+455,282$309,592→ 708,353 total
Sale
Common Stock
2025-07-09$15.00/sh−495,282$7,429,230→ 253,071 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-09−455,282→ 622,809 total
Exercise: $0.68Exp: 2025-08-21→ Common Stock (455,282 underlying)

Holdings

Common Stock
(indirect: See footnote)
2,202,604

Footnotes (6)

[F1]Includes 177,940 Unvested RSUs.
[F2]The sales reported by the Reporting Person were made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 09/16/2024. The shares sold primarily relate to 455,282 stock options that expire on 08/21/2025.
[F3]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
[F4]The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
[F5]The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.
[F6]25% of the shares subject to the option will vest on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.

Documents

1 file

4
wk-form4_1752268398.xmlPrimary
FORM 4

Issuer

Denali Therapeutics Inc.

CIK 0001714899

Entity typeother

Related Parties

1

filerCIK 0001724310

Filing Metadata

Form type: 4
Filed: Jul 10, 8:00 PM ET
Accepted: Jul 11, 5:13 PM ET
Size: 13.7 KB

View on SEC.gov